Home
Diseases
Bladder Cancer

Bladder Cancer

Disease

Disease Profile

Bladder cancer is a malignant growth arising in the urinary bladder, most commonly from urothelial cells. It can present as non-muscle-invasive, muscle-invasive, or metastatic disease and often first appears with hematuria.

Category: Urologic cancer
Prevalence: Globally, around 500,000 people are diagnosed with bladder cancer each year.

ICD Codes

C67.9

Related News

FDA Approvals and Pipeline Expansion Drive Bladder Cancer Therapeutics Market Growth

Jun 23, 2026

The bladder cancer therapeutics market is expanding with recent FDA approvals including INLEXZO for NMIBC and a KEYTRUDA-Padvev combination for MIBC, while the NMIBC market reached approximately USD 3 billion in 2025 across seven major markets. Ferring reported record revenues exceeding €2.5 billion in 2025, driven by Adstiladrin as its second major growth driver. A robust pipeline of emerging therapies is expected to further transform the market through 2036.

ctDNA Liquid Biopsy Shows Promise with New Clinical Evidence and Nanotechnology Advances

Jun 19, 2026

Clinical trial results support ctDNA-guided therapy for bladder cancer, with the phase III IMvigor011 trial showing improved survival outcomes. Standardisation efforts are underway through position papers from professional societies and consensus guidelines. Nanotechnology advances and AI integration are poised to improve ctDNA detection sensitivity for liquid biopsy applications.

Tempus AI Launches Preview Tool for Early Cancer Insights Within 24 Hours

May 30, 2026

Tempus has launched "Preview," an AI-powered tool that provides early cancer insights within one day of sample receipt to inform treatment planning. The tool focuses on high-impact biomarkers including MSI-H, EGFR mutations, and FGFR fusions across several cancer types. The launch aligns with expert emphasis on the critical role of early biomarker testing in personalizing therapy for EGFR-mutated NSCLC.

FDA accepts ImmunityBio sBLA for ANKTIVA plus BCG in papillary bladder cancer

May 20, 2026

ImmunityBio said the FDA accepted its sBLA for ANKTIVA plus BCG in BCG-unresponsive non-muscle invasive bladder cancer with papillary disease. The PDUFA date is Jan. 6, 2027.

ImmunityBio Says Saudi FDA Encouraged rBCG Filing and ANKTIVA Expansion Talks

May 17, 2026

ImmunityBio said the Saudi FDA encouraged submission of a regulatory package for recombinant BCG and opened talks on expanding ANKTIVA with checkpoint inhibitors to additional tumor types. The company expects to file the rBCG package within weeks.

FDA Approves Tecentriq for ctDNA-Guided Bladder Cancer and Venclexta Plus Acalabrutinib for CLL

May 16, 2026

FDA approves Genentech's Tecentriq as first ctDNA-guided adjuvant therapy for muscle-invasive bladder cancer, and Venclexta plus acalabrutinib as first all-oral fixed-duration regimen for CLL.

ImmunityBio launches ANKTIVA in Saudi Arabia after accelerated lung cancer approval

Apr 25, 2026

ImmunityBio has commercially launched ANKTIVA in Saudi Arabia for approved bladder and metastatic non-small cell lung cancer indications. The launch follows accelerated approval in lung cancer and extends the drug’s commercial rollout in MENA.

Urine DNA test may help predict BCG response in non-muscle invasive bladder cancer

Apr 22, 2026

A study in Cell suggests a urine DNA test may help identify which people with non-muscle invasive bladder cancer are likely to benefit from BCG immunotherapy. The test detected minimal residual disease after surgery and BCG treatment and distinguished recurrence risk based on tumour DNA findings.

Samsung Bioepis advances first new drug SBE303 into global Phase 1 trial

Apr 14, 2026

Samsung Bioepis plans to start a global Phase 1 trial of SBE303, its first independently developed new drug candidate targeting Nectin-4. Preclinical data showed tolerability up to 40 mg/kg in monkeys.

NHS greenlights durvalumab for muscle-invasive bladder cancer

Apr 10, 2026

Durvalumab has been approved for rollout on the NHS for muscle-invasive bladder cancer. In a trial of more than 1,000 patients, it cut the risk of progression by 32% versus standard care.

Related Clinical Trials

NCT ID	Title	Status	Phase
NCT07602010	Comparison of CT and MR (VI-RADS) Imaging for Local Bladder Cancer Staging	RECRUITING
NCT07581496	T1G3R-1 Trial: Detectability and Prognostic Value of ctDNA in T1 G3 Bladder Cancer	RECRUITING
NCT07568444	Enhancing Readability of Lay Abstracts and Summaries for Medical Knowledge Using Generative Artificial Intelligence (BRIDGE AI 3)	COMPLETED	PHASE2
NCT07545694	Study on the Effects of Drugs That Modulate the Endocannabinoid System on Spontaneous and Induced Contractility of the Human Detrusor Muscle	RECRUITING
NCT07525349	Immune-Stromal Landscape in Muscle-Invasive Bladder Cancer	NOT_YET_RECRUITING
NCT07514897	Detecting CREPT in Urine for Bladder Cancer Diagnosis and Monitoring	RECRUITING
NCT07510685	Closed-System Bladder Irrigation to Reduce Urinary Tract Infections After Endoscopic Urologic Surgery (IRIS Trial)	COMPLETED	NA
NCT07492628	Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma	RECRUITING	PHASE1
NCT07481123	COMPARISON OF OBTURATOR NERVE BLOCK TECHNIQUES IN TURBT	COMPLETED	NA
NCT07475403	Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer	RECRUITING	PHASE2